Shinozaki, Eiji

Early change in circulating tumor DNA as a potential predictor of response to chemotherapy in patients with metastatic colorectal cancer

Osumi, H., Shinozaki, E., Yamaguchi, K., & Zembutsu, H. (2019) · Scientific Reports

Colorectal Cancer Treatments and StudiesCancer Genomics and Diagnostics

Cited by 114

Multicenter phase I/II trial of napabucasin and pembrolizumab in patients with metastatic colorectal cancer (EPOC1503/SCOOP trial)

Kawazoe, A., Kuboki, Y., Shinozaki, E., Hara, H., Nishina, T., Komatsu, Y., Yuki, S., Wakabayashi, M., Nomura, S., Sato, A., et al. (2020) · Clinical Cancer Research

Cancer Immunotherapy and BiomarkersColorectal Cancer Treatments and Studies

Cited by 93

Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study

Shinozaki, E., Yoshino, T., Yamazaki, K., Muro, K., Yamaguchi, K., Nishina, T., Yuki, S., Shitara, K., Bando, H., Mimaki, S., et al. (2017) · British Journal of Cancer

Colorectal Cancer Treatments and StudiesLung Cancer Treatments and Mutations

Cited by 65

Clinical features associated with NeoRAS wild-type metastatic colorectal cancer A SCRUM-Japan GOZILA substudy

Osumi, H., Shinozaki, E., Nakamura, Y., Esaki, T., Yasui, H., Taniguchi, H., Satake, H., Sunakawa, Y., Komatsu, Y., Kagawa, Y., et al. (2024) · Nature Communications

Colorectal Cancer Treatments and StudiesCancer Genomics and Diagnostics

Cited by 17

A multi-institutional observational study evaluating the incidence and the clinicopathological characteristics of NeoRAS wild-type metastatic colorectal cancer

Osumi, H., Takashima, A., Ooki, A., Yoshinari, Y., Wakatsuki, T., Hirano, H., Nakayama, I., Okita, N., Sawada, R., Ouchi, K., et al. (2023) · Translational Oncology

Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments

Cited by 16

Acquired drug resistance conferred by a KRAS gene mutation following the administration of cetuximab: a case report

Osumi, H., Matsusaka, S., Shinozaki, E., Suenaga, M., Mingyon, M., Saiura, A., Ueno, M., Mizunuma, N., & Yamaguchi, T. (2013) · BMC Research Notes

Colorectal Cancer Treatments and StudiesLung Cancer Treatments and Mutations

Cited by 9

Artificial Intelligence in Clinical Oncology: From Productivity Enhancement to Creative Discovery

Kuno, M., Osumi, H., Udagawa, S., Yoshikawa, K., Ooki, A., Shinozaki, E., Ishikawa, T., Oba, J., Yamaguchi, K., & Sakurada, K. (2025) · Current Oncology

Artificial Intelligence in Healthcare and EducationAI in cancer detection

Cited by 7

Efficacy of anti-epidermal growth factor antibody rechallenge in RAS/BRAF wild-type metastatic colorectal cancer: a multi-institutional observational study

Fukuda, K., Osumi, H., Yoshinami, Y., Ooki, A., Takashima, A., Wakatsuki, T., Hirano, H., Nakayama, I., Ouchi, K., Sawada, R., et al. (2024) · Journal of Cancer Research and Clinical Oncology

Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments

Cited by 5